Peptide kappa opioid receptor ligands: potential for drug development.
While narcotic analgesics such as morphine, which act preferentially through mu opioid receptors, remain the gold standard in the treatment of severe pain, their use is limited by detrimental liabilities such as respiratory depression and drug dependence. Thus, there has been considerable interest in developing ligands for kappa opioid receptors (KOR) as potential analgesics and for the treatment of a variety of other disorders. These include effects mediated both by central receptors, such as antidepressant activity and a reduction in cocaine-seeking behavior, and activity resulting from the activation of peripheral receptors, such as analgesic and anti-inflammatory effects. While the vast majority of opioid receptor ligands that have progressed in preclinical development have been small molecules, significant advances have been made in recent years in identifying opioid peptide analogs that exhibit promising in vivo activity. This review will focus on possible therapeutic applications of ligands for KOR and specifically on the potential development of peptide ligands for these receptors.
Department of Medicinal Chemistry, University of Kansas, 1251 Wescoe Hall Dr., 4050 Malott Hall, Lawrence, Kansas 66045, USA. jaldrich@ku.edu
Jane V
JV
Aldrich
Jay P
JP
McLaughlin
D000818:Animals; D004298:Dopamine / Q000502:physiology; D004399:Dynorphins / Q000494:pharmacology; D006801:Humans; D008024:Ligands; D019151:Peptide Library; D010455:Peptides / Q000494:pharmacology*; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000037:antagonists & inhibitors / Q000187:drug effects*; D054852:Small Molecule Libraries
D008024:Ligands; D019151:Peptide Library; D010455:Peptides; D017473:Receptors, Opioid, kappa; D054852:Small Molecule Libraries; D004399:Dynorphins; D004298:Dopamine